Get Premium

Get Premium

Dominate Financial Markets with Stock Target Advisor Premium Features

Discover
Discover

Explore new stock opportunities and market trends for better investment decisions.
- Analyst Ratings & Stock Picks
- Top Picks By AI
- Latest Analyst Ratings
- Analyst Directory
- Worst Stocks
- Sector Ratings & Performance
- Smart Filters
- Best Penny Stocks
- Best Dividend Stocks
- Best Crypto Stocks
- Best Performing Stocks
- Worst Performing Stocks
- Highest Income ETFs
Research
Research

Access in-depth stock analysis and expert evaluations to guide your investments
- Automatic Selection
- Stocks/ETF Screener
- Query Builder
- Analyst Screener
- Automated Research Reports
- Best Stocks Filters
- Thematic Stock Screens
- Sector Stock Screens
Learn
Learn

Utilize our extensive educational resources designed to enhance your investing knowledge and skills
- Market News & Insights
- Stock Target Advisor Insights
- Tutorials
- Market News
- Stock Calendars
- Earnings Calendar
- IPO Calendar
- Splits Calendar
Watchlists & Portfolios
Watchlists & Portfolios

Easily manage, track, and optimize your stock selections for maximum returns
Engage
Engage

Connect with the investing community and access free widgets for better stock insights
Pricing

Guessing Isn’t a Strategy!

Use Research That Shows You What to Buy, When to Buy, and Why—Now Upto 70% OFF! Claim Now

Apellis Pharmaceuticals Inc (APLS) Stock Analyst Ratings & Price Targets

COMMON STOCK | Biotechnology | NSD

Target Add to Watchlist

Take a Tour

Buy

Average Analyst
Rating

Slightly Bearish

Stock Target Advisor
Analysis

Buy

Average User
Rating

Last Closing Price

USD 19.33

Change

-0.09 (-0.46%)

Market Cap

USD 2.44B

Volume

2.60M

Avg User Target

USD 48.33 (+150.03%)

APLS

Apellis Pharmaceuticals Inc (USD)

COMMON STOCK | NSD

USD 19.33

-0.09 ( -0.46%)

Watchlist

Apellis Pharmaceuticals Inc (APLS) Stock Forecast

Show ratings and price targets of :

All Analysts

Top Analysts

Average Analyst Target

USD 42.48

(+119.78%)

Based on the Apellis Pharmaceuticals Inc stock forecast from 16 analysts, the average analyst target price for Apellis Pharmaceuticals Inc is USD 42.48 over the next 12 months. Apellis Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Apellis Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Apellis Pharmaceuticals Inc’s stock price was USD 19.33. Apellis Pharmaceuticals Inc’s stock price has changed by -2.37% over the past week, -21.61% over the past month and -62.68% over the last year.

Analyst Ratings

Filter:

Show:

Target Price Action	Rating Action	Analyst	Rating	Price	Date

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What not to like

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.